- Supported exchanges /
- NASDAQ /
- CTNM.NASDAQ
Contineum Therapeutics, Inc. Class A Common Stock (CTNM NASDAQ) stock market data APIs
Contineum Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on discovering and developing novel oral small molecule therapies for neuroscience, inflammation, and immunology indications with high unmet need. Its lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis and progressive multiple sclerosis (MS). The company also develops PIPE-307, a novel, small molecule selective inhibitor of the muscarinic type 1 M1 receptor to treat depression and relapse remitting MS; and CTX-343, a peripherally-restricted LPA1R antagonist. Contineum Therapeutics, Inc. was formerly known as Pipeline Therapeutics, Inc. and changed its name to Contineum Therapeutics, Inc. in November 2023. The company was incorporated in 2009 and is headquartered in San Diego, California.
Contineum Therapeutics, Inc. Class A Common Stock Financial Data Overview
16.56 | |
16.46 | |
- | |
16.66 | |
16.42 | |
13.27-22 | |
493 M | |
18 994 K | |
0 | |
-0.39 | |
No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.
Contineum Therapeutics, Inc. Class A Common Stock Fundamental Data is available in our Financial Data APIs
- Net Revenue 0
- EBITDA -38 418 000
- Earnings Per Share -0.01
- Income Statements
- Balance Sheets
- Cash flows
of Fundamental API Data
Get Contineum Therapeutics, Inc. Class A Common Stock Earnings via APIs
- Latest Release 2024-08-14
- EPS/Forecast -0.35
Get Contineum Therapeutics, Inc. Class A Common Stock End-of-day Data via APIs
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Our 24/7 support would be happy to assist you via chat or email:
support@eodhistoricaldata.comVisit also: